DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

880
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Table 31–2
Apolipoproteins
AVERAGE
CONCENTRATION MOLECULAR SITES OF
APOLIPOPROTEIN (mg/dL) CHROMOSOME MASS (kDa) SYNTHESIS FUNCTIONS
ApoA-I 130 11 ~29 Liver, intestine Structural in HDL; LCAT cofactor;
ligand of ABCA1 receptor; reverse
cholesterol transport
ApoA-II 40 1 ~17 Liver Forms –S–S–complex with apoE-2
and E-3, which inhibits E-2 and E-3
binding to lipoprotein receptors
ApoA-V <1 11 ~40 Liver Modulates triglyceride incorporation
into hepatic VLDL; activates LPL
ApoB-100 85 2 ~513 Liver Structural protein of VLDL,
IDL, LDL; LDL receptor ligand
ApoB-48 Fluctuates according 2 ~241 Intestine Structural protein of chylomicrons
to dietary fat intake
ApoC-I 6 19 ~6.6 Liver LCAT activator; modulates receptor
binding of remnants
ApoC-II 3 19 8.9 Liver Lipoprotein lipase cofactor
ApoC-III 12 11 8.8 Liver Modulates receptor binding of
remnants
ApoE 5 19 34 Liver, brain, Ligand for LDL receptor and receptors
skin, gonads, binding remnants; reverse
spleen
cholesterol transport (HDL with apoE)
Apo(a) Variable (under 6 Variable Liver Modulator of fibrinolysis
genetic control)
apo, apolipoprotein; HDL, high-density lipoproteins; IDL, intermediate-density lipoproteins; LCAT, lecithin:cholesterol acyltransferase; LDL, low-density lipoproteins; LPL, lipoprotein lipase;
VLDL, very-low-density lipoproteins.